Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Human Immunodeficiency Virus
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 16 years and 35 years
- Gender
- Both males and females
Description
As of 18 December 2020, participant randomization is on hold due pending investigational product supply at the trial sites and not due to safety concerns. Sites will continue to recruit during this period to proactively plan for randomization upon investigational product availability.
As of 18 December 2020, participant randomization is on hold due pending investigational product supply at the trial sites and not due to safety concerns. Sites will continue to recruit during this period to proactively plan for randomization upon investigational product availability.
Tracking Information
- NCT #
- NCT04556981
- Collaborators
- Not Provided
- Investigators
- Study Director: Gates MRI Bill & Melinda Gates Medical Research Institute
Get Well Soon